Are matrix metalloproteinases relevant therapeutic targets for prostate cancer bone metastasis?

Current Oncology

Volumn 15, Issue 4, 2008, Pages 23-27

  Bonfil, R Daniel ^a   Fridman, R ^a   Mobashery, S ^b   Cher, M L ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NOTRE DAME   (United States)

Author keywords

Bone metastasis; Matrix metalloproteinases; Prostate cancer

Indexed keywords

ALENDRONIC ACID; BATIMASTAT; GELATINASE A; GELATINASE B; HYDROXAMIC ACID DERIVATIVE; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; PACLITAXEL; PRINOMASTAT; SB 3CT; UNCLASSIFIED DRUG;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; BONE METASTASIS; CANCER INHIBITION; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME STRUCTURE; HUMAN; NONHUMAN; PROSTATE CANCER; PROTEIN BINDING; PROTEIN EXPRESSION; REVIEW; RISK FACTOR;

EID: 54349104235     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.v15i4.216     Document Type: Review

References (40)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96.
2. Bubendorf L, Schöpfer A, Wagner U, et al. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol 2000;31:578-83.
3. Percival RC, Urwin GH, Harris S, et al. Biochemical and histological evidence that carcinoma of the prostate is associated with increased bone resorption. Eur J Surg Oncol 1987;13:41-9.
4. Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2002;2:584-93.
5. Keller ET, Brown J. Prostate cancer bone metastases promote both osteolytic and osteoblastic activity. J Cell Biochem 2004;91:718-29.
6. Chung LW. Prostate carcinoma bone-stroma interaction and its biologic and therapeutic implications. Cancer 2003;97(suppl):772-8.
7. Bonfil RD, Chinni S, Fridman R, Kim HR, Cher ML. Proteases, growth factors, chemokines, and the microenvironment in prostate cancer bone metastasis. Urol Oncol 2007;25:407-11.
8. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002;2:161-74.
9. Overall CM, Lopez-Otin C. Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat Rev Cancer 2002;2:657-72.
10. Rosenblum G, Meroueh S, Toth M, et al. Molecular structures and dynamics of the stepwise activation mechanism of a matrix metalloproteinase zymogen: challenging the cysteine switch dogma. J Am Chem Soc 2007;129:13566-74.
11. Stearns ME, Wang M. Effects of alendronate and Taxol on PC-3 ML cell bone metastases in SCID mice. Invasion Metastasis 1996;16:116-31.
12. Sanchez-Sweatman OH, Orr FW, Singh G. Human metastatic prostate PC3 cell lines degrade bone using matrix metalloproteinases. Invasion Metastasis 1998-1999; 18:297-305.
13. Wang J, Levenson AS, Satcher RL Jr. Identification of a unique set of genes altered during cell-cell contact in an in vitro model of prostate cancer bone metastasis. Int J Mol Med 2006;17:849-56.
14. Kanoh Y, Akahoshi T, Ohara T, et al. Expression of matrix metalloproteinase-2 and prostate-specific antigen in localized and metastatic prostate cancer. Anticancer Res 2002;22:1813-17.
15. Leto G, Badalamenti G, Arcara C, et al. Effects of zoledronic acid on proteinase plasma levels in patients with bone metastases. Anticancer Res 2006;26:23-6.
16. Nemeth JA, Harb JF, Barroso U Jr, He Z, Grignon DJ, Cher ML. Severe combined immunodeficient-hu model of human prostate cancer metastasis to human bone. Cancer Res 1999;59:1987-93.
17. Nemeth JA, Yousif R, Herzog M. et al. Matrix metalloproteinase activity, bone matrix turnover, and tumor cell proliferation in prostate cancer bone metastasis. J Natl Cancer Inst 2002;94:17-25.
18. Dong Z, Bonfil RD, Chinni S, et al. Matrix metalloproteinase activity and osteoclasts in experimental prostate cancer bone metastasis tissue. Am J Pathol 2005; 166:1173-86.
19. Wiesner C, Bonfil RD, Dong Z, et al. Heterogeneous activation of MMP-9 due to prostate cancer-bone interaction. Urology 2007;69:795-9.
20. Bergers G, Brekken R, McMahon G, et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2000;2:737-44.
21. Brown S, Bernardo M, Zhi-Hong L, et al. Potent and selective mechanism-based inhibition of gelatinases. J Am Chem Soc 2000;122:6799-800.
22. Ikejiri M, Bernardo MM, Bonfil RD, et al. Potent mechanism-based inhibitors for matrix metalloproteinases. J Biol Chem 2005;280:33992-4002.
23. Bonfil RD, Sabbota A, Nablia S, et al. Inhibition of human prostate cancer growth, osteolysis and angiogenesis in a bone metastasis model by a novel mechanism-based selective gelatinase inhibitor. Int J Cancer 2006;118:2721-6.
24. Engsig MT, Chen QJ, Vu TH, et al. Matrix metalloproteinase 9 and vascular endothelial growth factor are essential for osteoclast recruitment into developing long bones. J Cell Biol 2000;151:879-89.
25. Vu TH, Shipley JM, Bergers G, et al. MM-9/gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes. Cell 1998;93:411-22.
26. Holmbeck K, Bianco P, Caterina J, et al. MT1-MMP-deficient mice develop dwarfism, osteopenia, arthritis, and connective tissue disease due to inadequate collagen turnover. Cell 1999;99:81-92.
27. Cao J, Chiarelli C, Kozarekar P, Adler HL. Membrane type 1-matrix metalloproteinase promotes human prostate cancer invasion and metastasis. Thromb Haemost 2005;93:770-8.
28. Bair EL, Chen ML, McDaniel K, et al. Membrane type 1 matrix metalloprotease cleaves laminin-10 and promotes prostate cancer cell migration. Neoplasia 2005;7:380-9.
29. Cardillo MR, Di Silverio F, Gentile V. Quantitative immunohistochemical and in situ hybridization analysis of metalloproteinases in prostate cancer. Anticancer Res 2006;26:973-82.
30. Upadhyay J, Shekarriz B, Nemeth JA, et al. Membrane type 1-matrix metalloproteinase (MT1-MMP) and MMP-2 immunolocalization in human prostate: change in cellular localization associated with high-grade prostatic intraepithelial neoplasia. Clin Cancer Res 1999;5:4105-10.
31. Bonfil RD, Dong Z, Trindade Filho JC, et al. Prostate cancer-associated membrane type 1-matrix metalloproteinase: a pivotal role in bone response and intraosseous tumor growth. Am J Pathol 2007;170:2100-11.
32. Lynch CC, Hikosaka A, Acuff HB, et al. MMP-7 promotes prostate cancer-induced osteolysis via the solubilization of RANKL. Cancer Cell 2005;7:485-96.
33. Coussens LM, Fingleton B, Matrisian LM. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 2002;295:2387-92.
34. Ramnath N, Creaven PJ. Matrix metalloproteinase inhibitors. Curr Oncol Rep 2004;6:96-102.
35. Pavlaki M, Zucker S. Matrix metalloproteinase inhibitors (MMPIS): the beginning of phase I or the termination of phase III clinical trials. Cancer Metastasis Rev 2003;22:177-203.
36. Lopez-Otin C, Overall CM. Protease degradomics: a new challenge for proteomics. Nat Rev Mol Cell Biol 2002;3:509-19.
37. Overall CM, Kleifeld O. Tumour microenvironment-opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat Rev Cancer 2006;6:227-39.
38. Overall CM, Kleifeld O. Towards third generation matrix metalloproteinase inhibitors for cancer therapy. Br J Cancer 2006;94:941-6.
39. Nuti E, Tuccinardi T, Rossello A. Matrix metalloproteinase inhibitors: new challenges in the era of post broad-spectrum inhibitors. Curr Pharm Des 2007;13:2087-100.
40. Fisher JF, Mobashery S. Recent advances in MMP inhibitor design. Cancer Metastasis Rev 2006;25:115-36.